Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanTakuji Okusaka, Y Nimura, Junji Furuse et al.|British Journal of Cancer|2010Cited by 749
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trialsJuan W. Valle, Takuji Okusaka, Junji Furuse et al.|Annals of Oncology|2013Cited by 395
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialChigusa Morizane, Junji Furuse, Takuji Okusaka et al.|Annals of Oncology|2019Cited by 333
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Tanios Bekaii‐Saab, Nobumasa Mizuno et al.|Journal of Clinical Oncology|2023Cited by 100
Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinomaReiko Takayama, Kenji Yamao, Hidewaki Nakagawa et al.|Journal of Gastroenterology|2009Cited by 56